CN114908049A - Hdac6抑制剂在选择性诱导t细胞扩增中的用途 - Google Patents
Hdac6抑制剂在选择性诱导t细胞扩增中的用途 Download PDFInfo
- Publication number
- CN114908049A CN114908049A CN202110181103.2A CN202110181103A CN114908049A CN 114908049 A CN114908049 A CN 114908049A CN 202110181103 A CN202110181103 A CN 202110181103A CN 114908049 A CN114908049 A CN 114908049A
- Authority
- CN
- China
- Prior art keywords
- cells
- acy
- cell
- compound
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000001744 T-lymphocyte Anatomy 0.000 title claims abstract description 70
- WWGBHDIHIVGYLZ-UHFFFAOYSA-N N-[4-[3-[[[7-(hydroxyamino)-7-oxoheptyl]amino]-oxomethyl]-5-isoxazolyl]phenyl]carbamic acid tert-butyl ester Chemical compound C1=CC(NC(=O)OC(C)(C)C)=CC=C1C1=CC(C(=O)NCCCCCCC(=O)NO)=NO1 WWGBHDIHIVGYLZ-UHFFFAOYSA-N 0.000 title claims abstract description 49
- 102100022537 Histone deacetylase 6 Human genes 0.000 title claims abstract description 45
- 101000899330 Homo sapiens Histone deacetylase 6 Proteins 0.000 title claims abstract description 45
- 239000003112 inhibitor Substances 0.000 title claims abstract description 41
- 230000010261 cell growth Effects 0.000 title abstract description 7
- 150000001875 compounds Chemical class 0.000 claims abstract description 69
- QGZYDVAGYRLSKP-UHFFFAOYSA-N N-[7-(hydroxyamino)-7-oxoheptyl]-2-(N-phenylanilino)-5-pyrimidinecarboxamide Chemical compound N1=CC(C(=O)NCCCCCCC(=O)NO)=CN=C1N(C=1C=CC=CC=1)C1=CC=CC=C1 QGZYDVAGYRLSKP-UHFFFAOYSA-N 0.000 claims abstract description 47
- VLIUIBXPEDFJRF-UHFFFAOYSA-N 2-(n-(2-chlorophenyl)anilino)-n-[7-(hydroxyamino)-7-oxoheptyl]pyrimidine-5-carboxamide Chemical compound N1=CC(C(=O)NCCCCCCC(=O)NO)=CN=C1N(C=1C(=CC=CC=1)Cl)C1=CC=CC=C1 VLIUIBXPEDFJRF-UHFFFAOYSA-N 0.000 claims abstract description 35
- 238000000034 method Methods 0.000 claims abstract description 32
- 210000004027 cell Anatomy 0.000 claims description 120
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 28
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 claims description 20
- 230000035755 proliferation Effects 0.000 claims description 16
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 15
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 15
- 101001018097 Homo sapiens L-selectin Proteins 0.000 claims description 14
- 102100033467 L-selectin Human genes 0.000 claims description 14
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 claims description 13
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 claims description 13
- 102100030704 Interleukin-21 Human genes 0.000 claims description 13
- 102000000704 Interleukin-7 Human genes 0.000 claims description 13
- 108010002586 Interleukin-7 Proteins 0.000 claims description 13
- 108010074108 interleukin-21 Proteins 0.000 claims description 13
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 12
- 102000004127 Cytokines Human genes 0.000 claims description 10
- 108090000695 Cytokines Proteins 0.000 claims description 10
- -1 Tubastatin a Chemical compound 0.000 claims description 10
- 239000011324 bead Substances 0.000 claims description 9
- 230000001939 inductive effect Effects 0.000 claims description 9
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 claims description 8
- 102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 claims description 8
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 claims description 7
- 206010028980 Neoplasm Diseases 0.000 claims description 7
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims description 7
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims description 6
- 102000017578 LAG3 Human genes 0.000 claims description 6
- 108091008874 T cell receptors Proteins 0.000 claims description 6
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 102100027207 CD27 antigen Human genes 0.000 claims description 5
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims description 5
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 5
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 claims description 5
- 101001055145 Homo sapiens Interleukin-2 receptor subunit beta Proteins 0.000 claims description 5
- 101001043809 Homo sapiens Interleukin-7 receptor subunit alpha Proteins 0.000 claims description 5
- 102000003812 Interleukin-15 Human genes 0.000 claims description 5
- 108090000172 Interleukin-15 Proteins 0.000 claims description 5
- 102000000588 Interleukin-2 Human genes 0.000 claims description 5
- 108010002350 Interleukin-2 Proteins 0.000 claims description 5
- 102100026879 Interleukin-2 receptor subunit beta Human genes 0.000 claims description 5
- 102100021593 Interleukin-7 receptor subunit alpha Human genes 0.000 claims description 5
- BHUZLJOUHMBZQY-YXQOSMAKSA-N N-[4-[(2R,4R,6S)-4-[[(4,5-diphenyl-2-oxazolyl)thio]methyl]-6-[4-(hydroxymethyl)phenyl]-1,3-dioxan-2-yl]phenyl]-N'-hydroxyoctanediamide Chemical compound C1=CC(CO)=CC=C1[C@H]1O[C@@H](C=2C=CC(NC(=O)CCCCCCC(=O)NO)=CC=2)O[C@@H](CSC=2OC(=C(N=2)C=2C=CC=CC=2)C=2C=CC=CC=2)C1 BHUZLJOUHMBZQY-YXQOSMAKSA-N 0.000 claims description 5
- IYBURCQQEUNLDL-UHFFFAOYSA-N 2-[[1-(3-fluorophenyl)cyclohexyl]amino]-n-hydroxypyrimidine-5-carboxamide Chemical compound N1=CC(C(=O)NO)=CN=C1NC1(C=2C=C(F)C=CC=2)CCCCC1 IYBURCQQEUNLDL-UHFFFAOYSA-N 0.000 claims description 4
- PZBARTUEWCQNSN-UHFFFAOYSA-N 3-(benzylamino)-N-hydroxy-4-methylbenzamide Chemical compound C(C1=CC=CC=C1)NC=1C=C(C(=O)NO)C=CC=1C PZBARTUEWCQNSN-UHFFFAOYSA-N 0.000 claims description 4
- FIHKWEQJEDRIFS-UHFFFAOYSA-N 3-n-hydroxy-1-n-(2-phenylethyl)benzene-1,3-dicarboxamide Chemical compound ONC(=O)C1=CC=CC(C(=O)NCCC=2C=CC=CC=2)=C1 FIHKWEQJEDRIFS-UHFFFAOYSA-N 0.000 claims description 4
- BVQCFCYPFJOOAV-UHFFFAOYSA-N 4-bromo-n'-butylbenzohydrazide Chemical compound CCCCNNC(=O)C1=CC=C(Br)C=C1 BVQCFCYPFJOOAV-UHFFFAOYSA-N 0.000 claims description 4
- GISXTRIGVCKQBX-UHFFFAOYSA-N 7-[5-[bis(2-chloroethyl)amino]-1-methylbenzimidazol-2-yl]-n-hydroxyheptanamide Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCCCCC(=O)NO)=NC2=C1 GISXTRIGVCKQBX-UHFFFAOYSA-N 0.000 claims description 4
- FWXZZFONXWYSEF-UHFFFAOYSA-N N-hydroxy-4-[2-methoxy-5-[methyl-(2-methylquinazolin-4-yl)amino]phenoxy]butanamide Chemical compound ONC(CCCOC1=C(C=CC(=C1)N(C1=NC(=NC2=CC=CC=C12)C)C)OC)=O FWXZZFONXWYSEF-UHFFFAOYSA-N 0.000 claims description 4
- CTTSUGRYXUPYIO-UHFFFAOYSA-N ethyl 2-[(1-phenylcyclopropyl)amino]pyrimidine-5-carboxylate Chemical compound C1(=CC=CC=C1)C1(CC1)NC1=NC=C(C=N1)C(=O)OCC CTTSUGRYXUPYIO-UHFFFAOYSA-N 0.000 claims description 4
- KXWWYFKVBFUVIZ-SGWCAAJKSA-N n'-hydroxy-n-[(e)-[4-(n-phenylanilino)phenyl]methylideneamino]octanediamide Chemical compound C1=CC(/C=N/NC(=O)CCCCCCC(=O)NO)=CC=C1N(C=1C=CC=CC=1)C1=CC=CC=C1 KXWWYFKVBFUVIZ-SGWCAAJKSA-N 0.000 claims description 4
- NNQAQGDSGCGFER-UHFFFAOYSA-N n-hydroxy-2-(1-methylpyrrole-2-carbonyl)-3,4-dihydro-1h-isoquinoline-6-carboxamide Chemical compound CN1C=CC=C1C(=O)N1CC2=CC=C(C(=O)NO)C=C2CC1 NNQAQGDSGCGFER-UHFFFAOYSA-N 0.000 claims description 4
- LIIWIMDSZVNYHY-UHFFFAOYSA-N n-hydroxy-2-[(1-phenylcyclopropyl)amino]pyrimidine-5-carboxamide Chemical compound N1=CC(C(=O)NO)=CN=C1NC1(C=2C=CC=CC=2)CC1 LIIWIMDSZVNYHY-UHFFFAOYSA-N 0.000 claims description 4
- AVAOVICSJJIYRZ-UHFFFAOYSA-N n-hydroxy-4-[(2-methyl-3,4-dihydro-1h-pyrido[4,3-b]indol-5-yl)methyl]benzamide;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1N(C)CCC2=C1C1=CC=CC=C1N2CC1=CC=C(C(=O)NO)C=C1 AVAOVICSJJIYRZ-UHFFFAOYSA-N 0.000 claims description 4
- RFAZNTABYJYOAR-UHFFFAOYSA-N n-hydroxy-4-[2-[n-(2-hydroxyethyl)anilino]-2-oxoethyl]benzamide Chemical compound C=1C=CC=CC=1N(CCO)C(=O)CC1=CC=C(C(=O)NO)C=C1 RFAZNTABYJYOAR-UHFFFAOYSA-N 0.000 claims description 4
- JHDKZFFAIZKUCU-ZRDIBKRKSA-N pracinostat Chemical compound ONC(=O)/C=C/C1=CC=C2N(CCN(CC)CC)C(CCCC)=NC2=C1 JHDKZFFAIZKUCU-ZRDIBKRKSA-N 0.000 claims description 4
- 239000012190 activator Substances 0.000 claims description 3
- LJTSJTWIMOGKRJ-UHFFFAOYSA-N n-hydroxy-4-[(2-methyl-3,4-dihydro-1h-pyrido[4,3-b]indol-5-yl)methyl]benzamide;hydrochloride Chemical compound Cl.C1N(C)CCC2=C1C1=CC=CC=C1N2CC1=CC=C(C(=O)NO)C=C1 LJTSJTWIMOGKRJ-UHFFFAOYSA-N 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 238000000338 in vitro Methods 0.000 abstract description 4
- 230000000694 effects Effects 0.000 description 18
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 17
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 17
- 239000002773 nucleotide Substances 0.000 description 13
- 125000003729 nucleotide group Chemical group 0.000 description 13
- 210000005259 peripheral blood Anatomy 0.000 description 10
- 239000011886 peripheral blood Substances 0.000 description 10
- 230000001965 increasing effect Effects 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 8
- 238000004113 cell culture Methods 0.000 description 8
- 229920001917 Ficoll Polymers 0.000 description 7
- 102000003964 Histone deacetylase Human genes 0.000 description 5
- 108090000353 Histone deacetylase Proteins 0.000 description 5
- 230000022534 cell killing Effects 0.000 description 5
- 239000012737 fresh medium Substances 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 230000006052 T cell proliferation Effects 0.000 description 4
- 125000003275 alpha amino acid group Chemical group 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 238000003501 co-culture Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000002147 killing effect Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 229960002087 pertuzumab Drugs 0.000 description 4
- 210000000130 stem cell Anatomy 0.000 description 4
- 102100026882 Alpha-synuclein Human genes 0.000 description 3
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 description 3
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 description 3
- 101000652359 Homo sapiens Spermatogenesis-associated protein 2 Proteins 0.000 description 3
- 241000713666 Lentivirus Species 0.000 description 3
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 210000003071 memory t lymphocyte Anatomy 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 description 2
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 description 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 2
- 102100032530 Glypican-3 Human genes 0.000 description 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 2
- 101001014668 Homo sapiens Glypican-3 Proteins 0.000 description 2
- 101000600434 Homo sapiens Putative uncharacterized protein encoded by MIR7-3HG Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 229930012538 Paclitaxel Natural products 0.000 description 2
- 102100037401 Putative uncharacterized protein encoded by MIR7-3HG Human genes 0.000 description 2
- 230000021736 acetylation Effects 0.000 description 2
- 238000006640 acetylation reaction Methods 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 208000021601 lentivirus infection Diseases 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 230000025020 negative regulation of T cell proliferation Effects 0.000 description 2
- 229960001592 paclitaxel Drugs 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- VPVLEBIVXZSOMQ-UHFFFAOYSA-N 3-[[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol Chemical compound NC1=CC=CC(C=2NC3=NC=NC(OC=4C=C(O)C=CC=4)=C3C=2)=C1 VPVLEBIVXZSOMQ-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 101100510617 Caenorhabditis elegans sel-8 gene Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102100021455 Histone deacetylase 3 Human genes 0.000 description 1
- 102100038715 Histone deacetylase 8 Human genes 0.000 description 1
- 102000006947 Histones Human genes 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 101000899282 Homo sapiens Histone deacetylase 3 Proteins 0.000 description 1
- 101001032118 Homo sapiens Histone deacetylase 8 Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- 238000011579 SCID mouse model Methods 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 1
- 229960001467 bortezomib Drugs 0.000 description 1
- 201000007983 brain glioma Diseases 0.000 description 1
- 230000004611 cancer cell death Effects 0.000 description 1
- 210000004970 cd4 cell Anatomy 0.000 description 1
- 230000004640 cellular pathway Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 230000000779 depleting effect Effects 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000010362 genome editing Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 1
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 1
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 description 1
- 229960004942 lenalidomide Drugs 0.000 description 1
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 108010056030 retronectin Proteins 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2307—Interleukin-7 (IL-7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2315—Interleukin-15 (IL-15)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2321—Interleukin-21 (IL-21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/73—Hydrolases (EC 3.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Abstract
本发明涉及HDAC6抑制剂,例如化合物ACY‑1215及化合物ACY241用于体外T细胞处理的新用途及方法,使用其能够简便高效地诱导TSCM细胞扩增。
Description
技术领域
本发明涉及生物医药技术领域,具体涉及HDAC6抑制剂在选择性诱导T细胞扩增中的用途。
背景技术
记忆性干细胞样T细胞(T memory stem cells,TSCM)是T细胞的一个亚群,兼具记忆性细胞和干细胞的特点,处于记忆性T细胞早期分化阶段,能够分化为中央记忆性T细胞(central memory T cells,TCM)、效应记忆性T细胞(effector memory T cells,TEM)和效应性T细胞(effector T cells,TEF)。
现有研究表明,TSCM细胞与TCM细胞或TEM细胞相比,具有更强大的抗肿瘤能力,在机体内的生存能力也更加卓越,因此在肿瘤免疫治疗中具有很好的应用价值。由于TSCM细胞在人外周血T细胞中所占比例很少,约为2%-4%,如何诱导TSCM细胞大量增殖成为关键。
然而,现有技术中缺乏较为简便高效地扩增TSCM细胞的方法,并存在使T细胞的增殖效率降低的缺点,不利于将获得的细胞进行下一步的应用。比如,用化合物TWS119培养诱导TSCM细胞的同时,T细胞的增殖效率会大幅度降低,T细胞仅能扩增1-3倍。
这样的问题限制了TSCM细胞的应用,因此,需要一种能选择性扩增 TSCM细胞的方法,期望对T细胞的增殖效率影响较小,且不影响T细胞杀伤效率等与治疗能力相关的细胞特性。
发明内容
本发明提供了使用HDAC6抑制剂,具体为化合物ACY-1215、ACY241 选择性诱导T细胞扩增的方法,及HDAC6抑制剂在制备TSCM细胞中的用途。本发明人发现,HDAC6抑制剂如化合物ACY-1215、ACY241均在几乎不影响T细胞增殖的情况下,能够显著提升TSCM细胞占T细胞的比例,为体外扩增TSCM细胞提供了新的技术手段。
组蛋白去乙酰化酶(histone deacetylases,HDACs)可调节与细胞生长、转移、凋亡相关的多种细胞途径。HDACs抑制剂可以影响多种细胞效应,诱导细胞凋亡,阻碍细胞循环,抑制血管生成,其作为一种抗肿瘤制剂被广泛研究。HDAC6因其独特的结构和功能受到越来越多的关注,成为多种疾病潜在的治疗靶点,最受关注的主要是其在肿瘤及中枢神经系统中的作用。
研究证实,HDAC6抑制剂在治疗阿尔茨海默病、脑胶质瘤及神经保护方面的作用也受到越来越多研究者的关注。目前发现的HDAC6抑制剂主要包括ACY241、ACY-1215、Tubacin、Tubastatin A等,这些抑制剂具有相似但不尽相同的特性及应用,主要用于抗肿瘤及中枢神经系统保护等方面。因HDAC6具有较高的特异性,疗效好,不良反应少,具有良好的应用前景。
化合物ACY-1215的分子式为C24H27N5O3,名称为2-(二苯基氨基)-N-[7-(羟基氨基)-7-氧代庚基]-5-嘧啶羧酰胺,分子量为433.5,CAS号为:1316214-52-4,分子结构式如下所示:
化合物ACY-1215是一种有效的选择性HDAC6抑制剂,对HDAC6 的IC50值为4.7nM,对其他亚型的IC50值均>1μM,对HDAC8有微弱活性(IC50值为0.1μM)。ACY-1215在低剂量能有效诱导α-微管蛋白乙酰化,仅在较高剂量下引起组蛋白H3、H4上赖氨酸的乙酰化,证实了其对HDAC6的特异性抑制作用。
在波替单抗(硼替佐米)处理过的多发性骨髓瘤细胞(MM细胞)中,随着多泛素化蛋白水平的增加,该药可显著破坏聚集体的形成,表明波替单抗和该药联用可抑制蛋白酶体和聚集体形成。低剂量ACY-1215联合波替单抗可产生协同抗MM细胞增殖作用,同时延长内质网应激和促进细胞凋亡。在2种不同的异种移植SCID小鼠模型中,小鼠皮下注射人类MM细胞和静脉注射表达荧光素酶的人MM细胞后,联用上述两药,肿瘤生长明显减缓,小鼠总体存活时间显著延长。目前ACY-1215单用或与地塞米松、波替单抗、来那度胺联用的治疗方式正在进行Ⅰ期、Ⅱ期临床试验。
化合物ACY241的分子式为C24H26ClN5O3,名称为2-[(2-氯苯基)苯基氨基]-N-[7-(羟基氨基)-7-氧代庚基]-5-嘧啶甲酰胺,分子量为467.95,CAS 号为:1316215-12-9,分子结构式如下所示:
ACY241是一种口服有活性的选择性HDAC6抑制剂,对HDAC6和 HDAC3的IC50值分别为2.6和46nM。在多种实体瘤细胞系中,用ACY241 和紫杉醇(paclitaxel)联用,能显著增加癌细胞死亡率。在卵巢癌细胞中,较低浓度ACY241能选择性地抑制HDAC6,而高浓度导致Ⅰ类HDAC均被抑制,在体内具有较好的安全性。
目前没有关于HDAC6抑制剂类以及以上两种化合物在选择性促进记忆性干细胞样T细胞增殖中的相关报道。
具体而言,本发明包括以下内容。
1.诱导记忆性干细胞样T细胞增殖的方法,其包括使用HDAC6抑制剂处理包含或能够产生所述记忆性干细胞样T细胞的细胞群(如PBMC细胞、CD3+T淋巴细胞、CD8+T淋巴细胞或CD4+T淋巴细胞)。
2.根据项1所述的方法,其中,所述HDAC6抑制剂为选自Tubastatin A TFA,Tubastatin A,Pracinostat(SB939),UF010,SKLB-23bb,ACY-775, BRD73954,Citarinostat(化合物ACY-241),HPOB,MPI-5a,CG347B, Tubastatin A HCl,Tubacin,TH34,WT161,CAY10603,ACY-738,Tinostamustine(EDO-S101),BG45,Nexturastat A,SR-4370,化合物 ACY-1215中的一种或多种,优选选自化合物ACY-1215、化合物ACY241。
3.根据项2所述的方法,其中化合物ACY241的浓度为0.001至10uM,优选为0.001至0.1uM,更优选为0.001至0.03uM,独立地,化合物 ACY-1215的浓度为0.001至10uM,优选0.001至0.1uM,更优选0.001 至0.01uM。
4.根据项1~3中任一项所述的方法,其中所述记忆性干细胞样T细胞经过基因修饰,例如表达嵌合抗原受体(CAR)或T细胞受体(TCR)。
5.根据项4所述的方法,其中所述记忆性干细胞样T细胞包括为 CD45RO+或CD45RO-,且为CCR7+的记忆性干细胞样T细胞。
6.根据项5中任一项所述的方法,其中所述记忆性干细胞样T细胞进一步表达以下表型标志物中的一个或多个:CD45RA+、CD95+、CD27+、 CD62L+、CD28+、CD127+、PD1-、TIM3-、CD122+、PDL1-、LAG3-、CD3+、 CD4+和CD8+。
7.根据项1~4中任一项所述的方法,其中所述细胞群选自外周血单核细胞PBMC、CD3+T淋巴细胞、CD8+T淋巴细胞或CD4+T淋巴细胞。
8.根据项1所述的方法,包括使用细胞因子诱导记忆性干细胞样T细胞,所述细胞因子为以下一种或多种细胞因子的组合:IL2、IL21、IL7和 IL15,优选地,IL2的浓度为5至10000U/ml,IL7的浓度为0.1至100ng/ml, IL21的浓度为0.1至100ng/ml,IL15的浓度为0.1至100ng/ml。
9.根据项1所述的方法,包括使用细胞激活剂诱导扩增记忆性干细胞样T细胞,所述细胞激活剂为一个或多个包被抗CD3抗体和抗CD28抗体的磁珠。
10.HDAC6抑制剂在制备治疗或预防肿瘤的药物中的用途,包括利用 HDAC6抑制剂制备记忆性干细胞样T细胞,其中,所述HDAC6抑制剂为选自Tubastatin A TFA,TubastatinA,Pracinostat(SB939),UF010, SKLB-23bb,ACY-775,BRD73954,Citarinostat(ACY-241),HPOB,MPI-5a, CG347B,Tubastatin AHCl,Tubacin,TH34,WT161,CAY10603,ACY-738,Tinostamustine(EDO-S101),BG45,Nexturastat A,ACY-1215和SR-4370 中的一种或多种,优选选自化合物ACY-1215、化合物ACY241。
在本申请中,所述ACY241的浓度可以为0.001-100uM的范围,例如,浓度可以为0.001-100uM、0.001-10uM、0.001-3uM、0.001-1uM、0.001 -0.5uM、0.001-0.3uM、0.001-0.1uM、0.001-0.05uM、0.001-0.03uM、0.001 -0.01uM。所述ACY-1215的浓度可以为0.001-100uM,例如,浓度可以为 0.001-100uM、0.001-10uM、0.001-3uM、0.001-1uM、0.001-0.5uM、0.001 -0.3uM、0.001-0.1uM、0.001-0.05uM、0.001-0.03uM、0.001-0.01uM。
在某些实施方式中,其还包括以下步骤:分离获得外周血单核细胞 PBMC、CD3+T淋巴细胞、CD8+T淋巴细胞或CD4+T淋巴细胞。
在某些实施方式中,所述方法还包括:向上述分离的细胞例如PBMC 等加入一种或多种T细胞激活因子。所述T细胞激活因子包括:CD3抗体、CD28抗体、4-1BB抗体、CD80抗体、CD86抗体、PHA、PMA和/ 或离子霉素。这些因子可以以任何常用的形式,例如溶解在溶液中或固定在载体上的形式进行添加。具体的添加时机及频率例如为开始培养前后及培养中,例如为数天(例如1,2,3,4天)1次,只要能够实现本发明的效果即可,不限于此。
在某些实施方式中,所述方法还包括:向能够产生所述记忆性干细胞样T细胞的细胞群,例如经分离的所述PBMC加入一种或多种细胞因子;所述细胞因子包括选自下组的一种或多种:IL4、IL2、IL15、IL7、IL21、 IFN和TNF。同样地,这些细胞因子也可以以任何常用的形式,例如溶解在溶液中或固定在载体上的形式进行添加。具体的添加浓度及时机只要能够实现本发明的效果即可,不限于实施例给出的方式。
在某些实施方式中,所述方法还包括干细胞培养基;其中所述干细胞培养基包括选自下组的一种或多种:DMEM培养基、1640培养基、MEM 培养基、KBM-581培养基、AIM培养基、MACS培养基和X-VIVO培养基等常用于干细胞培养的培养基。
本发明的方法特别适用于CAR-T细胞,当用于CAR-T细胞(例如,本发明的分别表达GPC3-41BB-CAR、BCMA-41BB-CAR、CD19-41BB-CAR 的T细胞)时,CAR-T细胞的杀伤能力和CAR的表达稳定,基本不受影响。
附图说明
图1为加入不同浓度的化合物HDAC6抑制剂时T细胞增殖情况。
图2为HDAC6抑制剂提高TSCM细胞(T细胞)的细胞占比。A,共培养第7天的细胞占比,B为共培养第12天的细胞占比。
图3为HDAC6抑制剂对T细胞表型的影响示意图。A为以CCR7作为纵轴,CD45RO作为横轴的结果,B为以CD62L作为纵轴,CD8作为横轴的结果。
图4为加入HDAC6抑制剂后的CAR-T细胞参数。A为扩增倍数,B 为平均细胞直径,C为扩增倍数,D为平均细胞直径。
图5为HDAC6抑制剂促进TSCM细胞(CAR-T细胞)的形成。A为流式图,B为流式结果。
图6为HDAC6抑制剂对CAR-T细胞杀伤毒性的影响的细胞图。
图7为HDAC6抑制剂促进肿瘤细胞反复刺激后CAR-T细胞的增殖。 A为扩增倍数,B为平均细胞直径。
具体实施方式
以下通过实施例来进一步阐述本发明。但是应该理解,所述实施例只是举例说明的目的,并不意欲限制本发明的范围和精神。
实施例1构建用于制备CAR-T细胞的慢病毒载体
在本实施例中,制备了靶向GPC3、CD19、BCMA的CAR-T的细胞。具体为,首先人工合成了以下包含CAR结构的片段:
GPC3-41BB-CAR由前导序列(核苷酸如SEQ ID NO.10所示,氨基酸序列如SEQ IDNO.11所示,在以下CAR中使用了相同的前导序列)、GPC3 ScFv(核苷酸序列如SEQ ID NO.1所示,对应氨基酸序列如SEQ ID NO.7 所示)、CD8铰链区和跨膜区(核苷酸序列如SEQ IDNO.4所示)、41BB(核苷酸序列如SEQ ID NO.5所示)、CD3zeta(核苷酸序列如SEQ ID NO.6所示)从5’端至3’端依次拼接构建而成。
CD19-41BB-CAR由前导序列(同上)、CD19 ScFv(核苷酸序列如SEQ ID NO.2所示,对应氨基酸序列如SEQ ID NO.8所示)、CD8铰链区和跨膜区 (核苷酸序列如SEQ ID NO.4所示)、41BB(核苷酸序列如SEQ ID NO.5所示)、CD3zeta(核苷酸序列如SEQ ID NO.6所示)从5’端至3’端依次拼接构建而成。
BCMA-41BB-CAR由前导序列(同上)、BCMA ScFv(核苷酸序列如SEQ ID NO.3所示,对应氨基酸序列如SEQ ID NO.9所示)、CD8铰链区和跨膜区(核苷酸序列如SEQ ID NO.4所示)、41BB(核苷酸序列如SEQ ID NO.5 所示)、CD3zeta(核苷酸序列如SEQ ID NO.6所示)从5’端至3’端依次拼接构建而成。
将这些人工片段构建到慢病毒载体(LV100A,System Biosciences公司) 中,随后依照其说明书记载的方式转染获得慢病毒,分别得到 GPC3-41BB-CAR、BCMA-41BB-CAR、CD19-41BB-CAR慢病毒。
实施例2通过慢病毒感染获得CAR-T细胞
通过Ficoll分离液分离新鲜人外周血,获得大于1×107的外周血单核淋巴细胞(PBMC)。用PBS稀释抗人CD3及抗人CD28抗体(上海近岸生物科技有限公司,使其终浓度达到1μg/ml。然后,向细胞培养皿中加入稀释后的抗体混合液,然后将其均匀铺至细胞培养皿中,于室温孵育2小时。 2小时后,用PBS洗涤一次抗体混合液。随后,将分离的PBMC用含有Xvivo15培养基、5%FBS、200U/ml IL2 T或Xvivo15培养基、5%FBS、 20ng/ml IL21、10ng/ml IL7的淋巴细胞培养液进行重悬,使其终浓度达到 1×106个细胞/ml,加入放置抗体混合液的培养皿中于37℃、5%CO2培养 24小时,以激活T细胞。
取一定量的T细胞培养液,加入终浓度为1mg/ml的synperonic F108 混匀,于水浴锅加热至37℃,配制为感染试剂。随后,准备实验所需细胞培养皿。先取1mg/ml抗人CD3抗体和0.5mg/ml抗人CD28抗体用PBS 缓冲液按1:1000的体积比稀释并混匀,然后用retronectin(重组人纤维连接片段,TAKARA公司,T100B,1mg/ml)试剂按1:40的体积比稀释并混匀,然后将其均匀铺至细胞培养皿中,于室温孵育2小时。2小时后,用PBS 进行洗涤,细胞培养皿准备完成。
用所配感染试剂稀释已激活的T细胞,每皿细胞密度为1*106/ml,并按MOI=3的比例分别加入实施例1所制备的各种慢病毒并混匀。随后均匀铺在所述细胞培养皿中,进行慢病毒感染,从而获得了分别表达 GPC3-41BB-CAR、BCMA-41BB-CAR、CD19-41BB-CAR的T细胞。
感染后监测细胞密度,使这些感染后的细胞的密度维持在1×106个细胞/ml。14天后,观察到总细胞数的扩增在10-100倍的范围。
实施例3:不影响T细胞增殖的HDAC6抑制剂浓度。
将新鲜人外周血经Ficoll分离获得的外周血单个核细胞(Peripheral bloodmononuclear cell,PBMC),PBMC细胞(5*105/ml)与CD3/CD28磁珠 (Dynabeads)、IL21(25ng/ml)、IL7(20ng/ml)以及不同浓度(3,1,0.5,0.3, 0.1,0.03,0.01uM)的化合物ACY-1215或ACY241共培养12天,每2天换新鲜培养基并补加化合物和细胞因子,并取细胞进行台盼蓝染色计数,检测T细胞增殖倍数,将实验结果示于图1。
结果显示,如图1所示,在两组中,与对照相比,T细胞的相对扩增倍数均随化合物浓度的降低而增加,显示T细胞增殖抑制的逐步减轻。尤其是在为0.1,0.03,0.01uM的低剂量时,化合物ACY-1215及ACY241 均对T细胞增殖不显示抑制。
实施例4:HDAC6抑制剂促进TSCM细胞(T细胞)的增殖。
在本实施例中,发明人对浓度进一步进行细化,使用了0.1,0.03,0.01, 0.003,0.001uM的抑制剂化合物进行了共培养。
将新鲜人外周血经Ficoll分离获得外周血单个核细胞(Peripheral bloodmononuclear cell,PBMC),PBMC细胞(5*105/ml)与CD3/CD28磁珠 (Dynabeads)、IL21(25ng/ml)、IL7(20ng/ml)以及不同浓度(0.1,0.03,0.01, 0.003,0.001uM)的化合物ACY-1215或ACY241共培养12天,每2天换新鲜培养基并补加化合物和细胞因子。在第7天,第12天分别取细胞孵育,检测TSCM细胞的流式抗体(CD3、CD4、CD8、CD45RO、CD45RA、 CD62L、CCR7、CD95、CD122、CD127、CD27、CD28、PD1、TIM3、 PDL1、LAG3,均为赛默飞公司)并用流式细胞仪(BD公司)检测。实验结果分别示于图2A,B。
结果显示,在0.01,0.003,0.001uM的浓度下,化合物ACY-1215及 ACY241均能够显著提升CD45RO-CCR7+CD62L+CD95+即TSCM细胞占 CD3细胞比例、以及CD45RO-CCR7+CD62L+CD95+即TSCM细胞占CD8 细胞比例。在0.003,0.001uM的浓度下,化合物ACY-1215及ACY241能够显著提升CD45RO-CCR7+ CD62L+ CD95+即TSCM细胞占CD4细胞的比例。
实施例5:HDAC6抑制剂化合物对T细胞表型的影响。
将新鲜人外周血经Ficoll分离获得外周血单个核细胞(Peripheral bloodmononuclear cell,PBMC),PBMC细胞(5*105/ml)与CD3/CD28磁珠 (Dynabeads)、IL21(25ng/ml)、IL7(20ng/ml)以及0.01,0.003,0.001uM的化合物ACY-1215或ACY241共培养12天,每2天换新鲜培养基并补加化合物和细胞因子,第12天取细胞孵育检测TSCM细胞的流式抗体(CD3、 CD4、CD8、CD45RO、CD45RA、CD62L、CCR7、CD95、CD122、CD127、 CD27、CD28、PD1、TIM3、PDL1、LAG3,赛默飞公司)并用流式细胞仪(同上)检测。实验结果示于图3。A为以CCR7作为纵轴,CD45RO作为横轴的结果,B为以CD62L作为纵轴,CD8作为横轴的结果。
结果显示,关于HDAC6抑制剂化合物对T细胞表型的影响,在图3 中,在第一行的Q1象限中,对照为34.7%,0.01,0.003,0.001uM的化合物ACY-241组分别为45.8%,47.0%,57.1%;而0.01,0.003,0.001uM 的化合物ACY-1215组分别为52.5%,58.8%,55.2%。由此可知,与对照相比,在0.01,0.003,0.001uM的化合物ACY-1215及ACY241组中,为 CD45RO-CCR7+表型的T细胞的比例,即TSCM细胞的比例均显著提升。同时,与对照相比,各浓度的化合物ACY-1215及ACY241共培养后,CD8 和CD62L蛋白的表达稳定,表明对CD4/CD8表型无明显影响,能够持续维持归巢蛋白CD62L的高表达。
实施例6:化合物HDAC6抑制剂不影响CAR-T细胞增殖。
新鲜人外周血经Ficoll分离获得外周血单个核细胞(Peripheral bloodmononuclear cell,PBMC),同实施例2地制备了CAR-T细胞 GPC3-41BB-CAR。将CAR-T细胞(GPC3-41BB-CAR,5*105/ml)与 CD3/CD28磁珠(Dynabeads)、IL21(25ng/ml)、IL7(20ng/ml)以及不同浓度 (0.5,0.1,0.05uM,示于图4A,B;或0.1,0.03,0.01uM,示于图4C,D)化合物ACY-1215或ACY241共培养12天,每2天换新鲜培养基并补加化合物和细胞因子,并在不同时间点取细胞进行台盼蓝染色计数,检测 CAR-T细胞增殖效果。实验结果示于图4,A5表示化合物ACY-1215,A1 表示化合物ACY241。
结果显示,在0.5,0.1,0.05uM化合物ACY-1215及ACY241组中,以上化合物对CAR-T细胞的增殖曲线与对照组没有显著差别,CAR-T细胞的平均细胞直径亦保持同样的趋势。在0.1,0.03,0.01uM化合物 ACY241及0.03,0.01uM化合物ACY-1215组中,与对照相比,CAR-T细胞的扩增曲线有极轻微的降低,几乎没有影响。0.1,0.03,0.01uM浓度下化合物ACY241及化合物ACY-1215对平均细胞直径亦几乎没有影响。
实施例7:化合物HDAC6抑制剂促进TSCM细胞(CAR-T细胞) 的增殖。
将新鲜人外周血经Ficoll分离获得外周血单个核细胞(Peripheral bloodmononuclear cell,PBMC),制备CAR-T细胞(GPC3-41BB-CAR,5*105/ml) 与CD3/CD28磁珠(Dynabeads)、IL21(25ng/ml)、IL7(20ng/ml)以及0.1, 0.03,0.01uM化合物ACY-1215或化合物ACY241共培养12天,每2天换新鲜培养基并补加化合物和细胞因子,在第12天分别取细胞孵育检测 TSCM细胞的流式抗体,其中用于检测TSCM细胞特性的抗体使用了CD3、 CD4、CD8、CD45RO、CD45RA、CD62L、CCR7、CD95、CD122、CD127、 CD27、CD28、PD1、TIM3、PDL1、LAG3,用于检测上述CAR的流式抗体使用了靶向GPC3抗体(ACROBiosystems公司)并用流式细胞仪(同上)检测。实验结果示于图5,图5A中两种化合物浓度均为0.1uM,图5B 中从上到下分别以CAR,CD8,CD62L表达为横轴。
结果显示,如图5A所示,在化合物ACY-1215或ACY241组中,与对照组相比,在Q1象限中分布的CD45RO-CCR7+表型细胞比例升高(图 1),表明化合物ACY-1215或ACY241均能够显著提升TSCM细胞 (CD45RO-CCR7+)比例,同时,与对照组相比,在Q6象限中分布的表达PDL1+LAG3+的细胞比例降低,表明化合物ACY-1215或ACY241降低了耗竭性蛋白PDL1,LAG3的表达。
如图5B所示,与对照组(84.2%)相比,与0.1,0.03,0.01uM化合物ACY-1215及ACY241共培养时细胞的CAR表达率稳定(例如,87.6%, 86.6%,90.6%)。在化合物0.1,0.03,0.01uM ACY-1215或ACY241组中, CD8蛋白表达稳定,流式图显示CD62L蛋白表达稳定。表明化合物 ACY-1215或ACY241不会对CAR-T细胞中CAR的表达造成显著影响。
实施例8:HDAC6抑制剂对CAR-T细胞杀伤毒性的影响。
新鲜人外周血经Ficoll分离获得外周血单个核细胞(Peripheral bloodmononuclear cell,PBMC),将如实施例2地制备的CAR-T细胞 (GPC3-41BB-CAR,5*105/ml)与CD3/CD28磁珠(Dynabeads)、IL21(25 ng/ml)、IL7(20ng/ml)以及化合物ACY-1215(0.1uM)或ACY241(0.1uM) 共培养12天,在第7天,第12天分别取CAR-T细胞与Huh-7细胞(购自中科院细胞库)按细胞数1:1共孵育48h,显微镜拍照观察以及流式检测 CAR-T细胞对Huh-7细胞的杀伤效果,同时设置了仅Huh-7细胞(标记为 Huh-7组)和Huh-7细胞与普通T细胞共孵育(标记为Huh-7+T组)的对照组,将镜下照片示于图6,各组上方的图为与化合物共培养第7天的细胞,下方的图为共培养第12天的细胞。
结果显示:在Huh-7组与Huh-7+T组中,仍能够辨认出Huh-7细胞的形态,在化合物ACY-1215或ACY241处理组CAR-T细胞对Huh-7细胞均具有极高的杀伤效果,与对照组相似,可100%杀死Huh-7细胞。这是由于TSCM的体外细胞杀伤能力一般弱于终末期分化的细胞,试验表明化合物ACY-1215或ACY241处理对杀伤能力没有负面影响,不会造成细胞杀伤能力的损失。
实施例9:HDAC6抑制剂促进肿瘤细胞反复刺激后CAR-T细胞的增殖。
新鲜人外周血经Ficoll分离获得外周血单个核细胞(Peripheral bloodmononuclear cell,PBMC),上述制备的CAR-T细胞(GPC3-41BB-CAR, 5*105/ml)与CD3/CD28磁珠(Dynabeads)、IL21(25ng/ml)、IL7(20ng/ml) 以及化合物ACY-1215(0.5,0.1,0.05uM)共培养12天,在第12天分别取CAR-T细胞与辐照(X-RAD细胞辐照仪,辐照剂量为30Gy)的Huh7细胞按细胞数1:1共培养,培养基为Xvivo15,每4天重新补加辐照的Huh7 细胞作为一次刺激,共刺激2次,每次用台盼蓝计数细胞增殖情况。
实验结果如图7所示,与对照组相比,化合物ACY-1215处理组在0.5, 0.1,0.05uM浓度下时,第8天CAR-T细胞的扩增倍数及趋势均高于对照组,CAR-T细胞的平均细胞直径亦保持同样的趋势。
综上所述,在使用HDAC6抑制剂处理包含或能够产生所述记忆性干细胞样细胞的细胞群时,无论是分离的PBMC还是经过基因编辑得到的 CAR-T细胞,在处理一段时间后,都能够显著提升TSCM细胞占T细胞比例,且对T细胞增殖效果没有显著的影响。
由于HDAC6抑制剂是在体内具有较好的安全性的试剂,因此可以期待HDAC6抑制剂在治疗和/或预防癌症、自身免疫疾病或病毒感染疾病中的应用,尤其是CAR-T细胞中TSCM细胞比例的增加,可被用于对受试者进行个性化诊断和治疗等。
综上,本申请提供了诱导干细胞样细胞增殖的方法。该方法能够快速、简便和/或稳定地诱导干细胞样细胞增殖。本申请提供的方法可以在体外诱导记忆性干细胞样T细胞增殖。此外,本申请提供的方法能够被借鉴用以制备干细胞样细胞增殖诱导剂。本申请提供的方法还能够用于治疗和/或预防癌症、自身免疫疾病或病毒感染疾病。此外,本申请的方法可被用于对受试者进行个性化诊断和治疗。例如,能用于诱导包含经T细胞表达嵌合抗原受体(CAR)或T细胞受体(TCR)修饰的T细胞的记忆性干细胞样T细胞的增殖。
Claims (10)
1.诱导记忆性干细胞样T细胞增殖的方法,其包括使用HDAC6抑制剂处理包含或能够产生所述记忆性干细胞样T细胞的细胞群(如PBMC细胞、CD3+T淋巴细胞、CD8+T淋巴细胞或CD4+T淋巴细胞)。
2.根据权利要求1所述的方法,其中,所述HDAC6抑制剂为选自Tubastatin A TFA,Tubastatin A,Pracinostat(SB939),UF010,SKLB-23bb,ACY-775,BRD73954,Citarinostat(化合物ACY-241),HPOB,MPI-5a,CG347B,Tubastatin A HCl,Tubacin,TH34,WT161,CAY10603,ACY-738,Tinostamustine(EDO-S101),BG45,Nexturastat A,SR-4370,化合物ACY-1215中的一种或多种,优选选自化合物ACY-1215、化合物ACY241。
3.根据权利要求2所述的方法,其中化合物ACY241的浓度为0.001至10uM,优选为0.001至0.1uM,更优选为0.001至0.03uM,独立地,化合物ACY-1215的浓度为0.001至10uM,优选0.001至0.1uM,更优选0.001至0.01uM。
4.根据权利要求1~3中任一项所述的方法,其中所述记忆性干细胞样T细胞经过基因修饰,例如表达嵌合抗原受体(CAR)或T细胞受体(TCR)。
5.根据权利要求4所述的方法,其中所述记忆性干细胞样T细胞包括为CD45RO+或CD45RO-,且为CCR7+的记忆性干细胞样T细胞。
6.根据权利要求5中任一项所述的方法,其中所述记忆性干细胞样T细胞进一步表达以下表型标志物中的一个或多个:CD45RA+、CD95+、CD27+、CD62L+、CD28+、CD127+、PD1-、TIM3-,CD122+、PDL1-、LAG3-、CD3+、CD4+和CD8+。
7.根据权利要求1~4中任一项所述的方法,其中所述细胞群选自外周血单核细胞PBMC、CD3+T淋巴细胞、CD8+T淋巴细胞或CD4+T淋巴细胞。
8.根据权利要求1所述的方法,包括使用细胞因子诱导记忆性干细胞样T细胞,所述细胞因子为以下一种或多种细胞因子的组合:IL2、IL21、IL7和IL15,优选地,IL2的浓度为5至10000U/ml,IL7的浓度为0.1至100ng/ml,IL21的浓度为0.1至100ng/ml,IL15的浓度为0.1至100ng/ml。
9.根据权利要求1所述的方法,包括使用细胞激活剂诱导扩增记忆性干细胞样T细胞,所述细胞激活剂为一个或多个包被抗CD3抗体和抗CD28抗体的磁珠。
10.HDAC6抑制剂在制备治疗或预防肿瘤的药物中的用途,包括利用HDAC6抑制剂制备记忆性干细胞样T细胞,其中,所述HDAC6抑制剂为选自Tubastatin A TFA,Tubastatin A,Pracinostat(SB939),UF010,SKLB-23bb,ACY-775,BRD73954,Citarinostat(ACY-241),HPOB,MPI-5a,CG347B,Tubastatin A HCl,Tubacin,TH34,WT161,CAY10603,ACY-738,Tinostamustine(EDO-S101),BG45,Nexturastat A,ACY-1215和SR-4370中的一种或多种,优选选自化合物ACY-1215、化合物ACY241。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110181103.2A CN114908049A (zh) | 2021-02-10 | 2021-02-10 | Hdac6抑制剂在选择性诱导t细胞扩增中的用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110181103.2A CN114908049A (zh) | 2021-02-10 | 2021-02-10 | Hdac6抑制剂在选择性诱导t细胞扩增中的用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114908049A true CN114908049A (zh) | 2022-08-16 |
Family
ID=82761054
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110181103.2A Pending CN114908049A (zh) | 2021-02-10 | 2021-02-10 | Hdac6抑制剂在选择性诱导t细胞扩增中的用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114908049A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024067673A1 (zh) * | 2022-09-30 | 2024-04-04 | 北京昌平实验室 | 肿瘤抗原特异性记忆性cd8 t细胞的鉴定、体外扩增及应用方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103861107A (zh) * | 2014-03-04 | 2014-06-18 | 肖文华 | 一种药物组合物及其用途 |
CN106399243A (zh) * | 2016-09-30 | 2017-02-15 | 中山大学 | 一种干细胞样记忆性t细胞体外诱导剂及方法 |
US20170056402A1 (en) * | 2014-04-05 | 2017-03-02 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Histone deacetylase 6 inhibition for enhancing t-cell function during anti-tumor response and tumor-peptide vaccination |
CN107586758A (zh) * | 2017-11-03 | 2018-01-16 | 广西医科大学 | 一种干细胞样记忆性t细胞体外诱导剂及诱导方法 |
US20200323848A1 (en) * | 2016-06-09 | 2020-10-15 | Dana-Farber Cancer Institute, Inc. | Methods of use and pharmaceutical combinations of hdac inhibitors with bet inhibitors |
-
2021
- 2021-02-10 CN CN202110181103.2A patent/CN114908049A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103861107A (zh) * | 2014-03-04 | 2014-06-18 | 肖文华 | 一种药物组合物及其用途 |
US20170056402A1 (en) * | 2014-04-05 | 2017-03-02 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Histone deacetylase 6 inhibition for enhancing t-cell function during anti-tumor response and tumor-peptide vaccination |
US20200323848A1 (en) * | 2016-06-09 | 2020-10-15 | Dana-Farber Cancer Institute, Inc. | Methods of use and pharmaceutical combinations of hdac inhibitors with bet inhibitors |
CN106399243A (zh) * | 2016-09-30 | 2017-02-15 | 中山大学 | 一种干细胞样记忆性t细胞体外诱导剂及方法 |
CN107586758A (zh) * | 2017-11-03 | 2018-01-16 | 广西医科大学 | 一种干细胞样记忆性t细胞体外诱导剂及诱导方法 |
Non-Patent Citations (2)
Title |
---|
ANDRESSA S. LAINO等: "HDAC6 selective inhibition of melanoma patient T-cells augments anti-tumor characteristics", 《JOURNAL FOR IMMUNOTHERAPY OF CANCER》, vol. 7, 6 February 2019 (2019-02-06), pages 6 - 7 * |
JOOEUN BAE等: "Histone deacetylase (HDAC) inhibitor ACY241 enhances antitumor activities of antigen-specific central memory cytotoxic T lymphocytes against multiple myeloma and solid tumors", 《LEUKEMIA》, vol. 32, no. 9, 30 September 2018 (2018-09-30), pages 1932 - 1947, XP036583019, DOI: 10.1038/s41375-018-0062-8 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024067673A1 (zh) * | 2022-09-30 | 2024-04-04 | 北京昌平实验室 | 肿瘤抗原特异性记忆性cd8 t细胞的鉴定、体外扩增及应用方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230399615A1 (en) | Icos critically regulates the expansion and function of inflammatory human th17 cells | |
US10273454B2 (en) | Means and methods for influencing the stability of antibody producing cells | |
KR101279172B1 (ko) | 림프구의 제조 방법 | |
AU2012351347B2 (en) | Process of expanding T cells | |
JP5156382B2 (ja) | T細胞集団の製造方法 | |
JP5805089B2 (ja) | 細胞集団の製造方法 | |
AU2003221073B2 (en) | Process for producing cytotoxic lymphocyte | |
JP4949607B2 (ja) | 抗原特異的細胞傷害性t細胞拡大培養方法 | |
US8927273B2 (en) | Process for producing cytotoxic lymphocytes | |
Chi et al. | T-cell exhaustion and stemness in antitumor immunity: Characteristics, mechanisms, and implications | |
CN114908049A (zh) | Hdac6抑制剂在选择性诱导t细胞扩增中的用途 | |
US20180305665A1 (en) | Method for Enrichment and Expansion of Virus Antigen-Specific T Cells | |
JPWO2008143255A1 (ja) | 細胞集団の製造方法 | |
CN110662831A (zh) | 制备和使用胚胎间充质祖细胞的方法 | |
CN106947738B (zh) | microRNA-4281的新用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20240104 Address after: 223000 on the west side of Ninglian Road and the south side of Nenjiang Road in Huaiyin District, Huai'an City, Jiangsu Province (Building 17) Applicant after: Huai'an Dingwei medical laboratory Co.,Ltd. Address before: Room 947-5, block a, phase I, Zhongdan Ecological Life Science Industrial Park, no.3-1, xinjinhu Road, Jiangbei new district, Nanjing City, Jiangsu Province, 210000 Applicant before: Jiangsu Jicui Institute of medical immunology Co.,Ltd. |